JAB Holdings B.V.

Amsterdam

Interim Condensed Financial Statements as at and for the six months period ended 30 June 2021

Index	Page
Report of the Board of Directors	3
Interim Condensed Financial Statements as at and for the six months period ended 30 June 2021	
Interim Condensed Statement of Financial Position as of 30 June 2021	4
Interim Condensed Statement of Profit or Loss and Other Comprehensive Income for the six months period ended 30 June 2021	5
Interim Condensed Statement of Changes in Equity for the six months period ended 30 June 2021	6
Interim Condensed Cash Flow Statement for the six months period ended 30 June 2021	7
Notes to the interim condensed financial statements	8

Report of the Board of Directors

In accordance with article 394 paragraph 4 Book 2 of the Dutch Civil Code, the report of the board of directors can be inspected at the office of the entity. On request, a complete or partial copy will be available at a fee to cover the costs. For JAB Holding Company Sarl consolidated board report, we refer to the consolidated financial statements of JAB Holding Company Sarl published on the company's website.

Interim Condensed Statement of Financial Position as of 30 June 2021

(after appropriation of result)

		30 Jun	e 2021	31 Decemb	er 2020 1)
	note	in \$k	in \$k	in \$k	in \$k
Non-current assets					
Investments in subsidiaries	4	33,990,478		30,250,071	
Other investments	5	263,897		131,713	
Loans to investments	6	0		117,089	
Other assets	8	8,663		9,781	
			34,263,038		30,508,654
Current assets					
Other investments	5	0		447	
Loans to investments	6	9,084		0	
Other loans	7	30,634		50,867	
Other assets	8	988		6,111	
Cash and cash equivalents	9	2,763,074		2,672,667	
			2,803,780		2,730,092
		-	37,066,818	-	33,238,746
Charabaldar'a aguitu	10				
Shareholder's equity	10.1	22		22	
Share capital					
Share premium	10.2	6,026,661		6,670,911	
Legal reserve	10.3	15,551,844		11,877,897	
Foreign currency translation reserve	40.4	-		(121,095)	
Retained earnings	10.4	4,963,868		4,439,216	
			26,542,395		22,866,951
Non-current liabilities					
Borrowings	12	9,658,266		9,445,788	
Other liabilities	13	1,316		1,435	
			9,659,582		9,447,223
Current liabilities					
Borrowings	12	802,714		828,524	
Other liabilities	13	62,127		96,048	
		, ,	864,841		924,572
		-	37,066,818	-	33,238,746
				-	

¹⁾ Comparative information has been re-presented due to a change in presentation currency from EUR to US Dollar.

Interim Condensed Statement of Profit or Loss and Other Comprehensive Income for the six months period ended 30 June 2021

		For the six months	For the six months
		ended	ended
		30 June 2021	30 June 2020 ¹⁾
	note	in \$k	in \$k
Net gain / (loss) on investments in subsidiaries and other			
investments	14	3,332,971	(5,222,844)
Dividend income	15	358,466	80,585
Finance income	17	279,159	41,499
Finance expenses	17	(112,743)	(89,453)
General and administrative expenses	18	(10,731)	(7,083)
Other expenses	19	(7,879)	0
Profit / (loss) before income taxes		3,839,243	(5,197,296)
Income tax expense	20	(122)	(166)
Profit / (loss) for the period		3,839,121	(5,197,462)
Items that will not be reclassified			
to profit and loss:			
Other comprehensive (loss) for the period		0	(173,122)
Total comprehensive income / (loss) for the period			
attributable to equity holder		3,839,121	(5,370,584)

¹⁾ Comparative information has been re-presented due to a change in presentation currency from EUR to US Dollar.

Interim Condensed Statement of Changes in Equity for the six months period ended 30 June 2021

					Foreign		
		Share	Share		currency	Retained	Total
		capital	premium L	_egal reserve	translation	earnings	equity
	note	in \$k	in \$k	in \$k	in \$k	in \$k	in \$k
Balance as of 1 January 2020 ¹⁾		22	7,729,445	12,709,749	(2,092,711)	6,338,419	24,684,924
Contributions	10.2	-	15,000	-	-	-	15,000
Repayment of share premium	10.2	-	(621,034)	-	-	-	(621,034)
Other comprehensive income for the period		-	-	-	(173,122)	-	(173,122)
Loss for the period		-	-	(2,072,845)	-	(3,124,617)	(5,197,462)
Total comprehensive loss	_	-	-	(2,072,845)	(173,122)	(3,124,617)	(5,370,584)
Balance as of 30 June 2020 ¹⁾		22	7,123,411	10,636,904	(2,265,833)	3,213,802	18,708,306
Balance as of 1 January 2021		22	6,670,911	11,877,897	(121,095)	4,439,216	22,866,951
Effect of change in functional currency		0	(480,572)	1,263,507	121,095	(904,030)	-
Contributions	10.2	-	40,000	-	-	-	40,000
Share-based payments transactions	11	-	(62,089)	-	-	-	(62,089)
Repayment of share premium	10.2	-	(141,589)	-	-	-	(141,589)
Profit for the period		-	-	2,410,440	-	1,428,681	3,839,121
Total comprehensive income		-	-	2,410,440	-	1,428,681	3,839,121
Balance as of 30 June 2021		22	6,026,661	15,551,844	-	4,963,868	26,542,395

¹⁾ Comparative information has been re-presented due to a change in presentation currency from EUR to US Dollar.

Interim Condensed Cash Flow Statement for the six months period ended 30 June 2021

ended 30 June 2021 ended 30 June 2021 in Sk Cash flows from operating activities in Sk in Sk Profit / (loss) for the period 3.839,121 (5.197,462) Adjustments for: 216 194 Depreciation 216 194 Share-based payment transactions 11 7.879 - Dividend income 15 3588,466 (80,585) Net (gain) / loss from change in fair value of investments in subsidiaries and other investments 14 (3,332,971) 5,222,844 Income tax expense 20 1122 166 161 47,954 Other adjustments (11 (190) (18) (190) (18) Income taxe spaid (10,705) (6,907) (14,769) (14,769) Income taxes paid (122) (66) (14,769) (14,96) Dividends received 15 358,466 80,585 (24,108) (1090,817) Cash flows from investments in subsidiaries 4,5 821,608 1,090,817 Contribution payments for minvestiments in subsidia			For the six months	For the six months
Cash flows from operating activities			ended 30 June 2021	ended 30 June 2020 ¹⁾
Profit / (loss) for the period 3,839,121 (5,197,462) Adjustments for: 216 194 Depreciation 216 194 Share-based payment transactions 11 7,879 - Dividend income 15 (358,466) (80,585) Net (gain) / loss from change in fair value of investments in subsidiaries and other investments 14 (3,32,971) 5,222,844 Income tax expense 20 122 166 Finance income and finance expenses 17 (166,416) 47,954 Other adjustments (132) 284 Change in other receivables (32) 284 Change in other current liabilities 1,494 4,494 Cash flows from investing activities (122) (r66) Income taxe spaid (122) (r66) Cash flows from investiments in subsidiaries 4,5 21,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 5 563 - Dividend's received 5 563 - -		note	in \$k	in \$k
Adjustments for: 216 194 Depreciation 216 194 Share-based payment transactions 11 7,879 - Dividend income 15 (358,466) (80,585) Net (gain) / loss from change in fair value of investments in subsidiaries and other investments 14 (3,332,971) 5,222,844 Income tax expense 20 122 166 Finance income and finance expenses 20 122 166 Charge in other current liabilities 1,494 4,494 Cash flows from net foreign exchange results 1,494 4,494 Cash flows from net of reign exchange results 1,122 (66) Income taxe spaid 122 (55) Dividends received 15 558,466 80,565 Cash flows from investing activities 4,5 52,609 (19,00,817 Contribution payments to and acquisition of investments in subsidiaries 4,5 56,667 43,668,333 Disposal of other investments 5 (1,087,567) (4,368,333) 56,563 - Interest received 2,772 11,726 11,726 - - <td>Cash flows from operating activities</td> <td></td> <td></td> <td></td>	Cash flows from operating activities			
Depreciation 216 194 Share-based payment transactions 11 7,879	Profit / (loss) for the period		3,839,121	(5,197,462)
Share-based payment transactions 11 7,879 Dividend income 15 (358,466) (80,585) Net (gain) / loss from change in fair value of investments in subsidiaries and other investments 14 (3,332,971) 5,222,844 Income tax expense 20 122 166 Finance income and finance expenses 20 (100,705) (6,907) Charge in other current liabilities (43,244) (14,769) (16,967) Charge in other current liabilities (43,244) (14,769) (16,967) Income taxes paid (122) (66) (16,971) Net cash used in operating activities 4,5 (22,609) (16,954) Dividends received 15 358,466 80,585 Cash flows from investments in subsidiaries 4,5 (21,08) 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 4,5 (3,67,763) (4,368,353) Disposal of other investments 5 563 - - Interest received 6,7 (244,296) (37,78,30) Repayme	Adjustments for:			
Dividend income 15 (358,466) (80,585) Net (gain) / loss from change in fair value of investments in subsidiaries and other investments 14 (3,332,971) 5,222,844 Income tax expense 20 122 166 Finance income and finance expenses 17 (16,616) 47,954 Other adjustments (10,705) (6,907) Change in other receivables (32) 284 Change in other receivables (3,32,971) 5,222,844 Change in other receivables (10,705) (6,907) Change in other current liabilities (3,32,921) (14,769) Income taxes paid (122) (56) Net cash used in operating activities (3,32,971) (4,368,35) Dividends received 15 358,466 80,585 Capital repayments from investments in subsidiaries 4,5 821,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 4,5 563 - Interest received 2,772 11,726 (3,77,830) Repayment loans 6,7	Depreciation		216	194
Net (gain) / loss from change in fair value of investments in subsidiaries and other investments 14 (3,332,971) 5,222,844 Income tax expense 20 122 166 Finance income and finance expenses 17 (166,416) 47,954 Other adjustments (190) (18) Change in other receivables (32) 284 Change in other current liabilities (43,244) (14,769) Income taxes paid (122) (56) Net cash used in operating activities (52,609) (16,954) Cash flows from investing activities (52,609) (16,954) Dividends received 15 358,466 80,555 Capital repayments form investments in subsidiaries 4,5 (1,087,567) (4,368,353) Disposal of other investments 5 563 - Interest received 6,7 (244,296) (377,830) Repayment loans 6,7 (46,343) (3,163,901) Interest received 14 - - New loans 6,7 (6,234) (3,163,901)	Share-based payment transactions	11	7,879	-
subsidiaries and other investments 14 (3,332,971) 5,222,844 Income tax expense 20 122 166 Finance income and finance expenses 17 (166,416) 47,954 Other adjustments (190) (18) (190) (18) Change in other receivables (32) 284 Change in other current liabilities 1,494 4,494 Cash flows from net foreign exchange results (43,244) (14,769) Income tax exp aid (122) (56) Net cash used in operating activities (52,609) (16,954) Dividends received 15 358,466 80,585 Dividends received 1,522,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 4,5 563 - Interest received 2,772 11,726 - New loans 6,7 (244,296) (377,830) Repayment loans Activities 6,7 6,744,296 (3,74,500) Contribution of property, plant and equipment - - - <td>Dividend income</td> <td>15</td> <td>(358,466)</td> <td>(80,585)</td>	Dividend income	15	(358,466)	(80,585)
Income tax expense 20 122 166 Finance income and finance expenses 17 (166,416) 47,954 Other adjustments (190) (18) Change in other receivables (32) 284 Change in other receivables (32) 284 Change in other current liabilities 1,494 4,494 Cash flows from net foreign exchange results (122) (66) Income taxes paid (52,609) (16,554) Cash flows from investing activities (52,609) (16,963) Dividends received 15 358,466 80,585 Capital repayments for investments in subsidiaries 4,5 821,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 4,5 61,087,567) (4,368,353) Disposal of other investments 5 663 - - Interest received 2,772 11,726 (43,68,353) - Net cash used in investing activities 6,7 (244,296) (377,830) - Repayment of share premium <td< td=""><td>Net (gain) / loss from change in fair value of investments in</td><td></td><td></td><td></td></td<>	Net (gain) / loss from change in fair value of investments in			
Finance income and finance expenses 17 (166,416) 47,954 Other adjustments (190) (18) Change in other receivables (32) 284 Change in other current liabilities 1,494 4,494 Cash flows from net foreign exchange results (43,244) (14,769) Income taxes paid (52,609) (16,954) Net cash used in operating activities (52,609) (16,954) Dividends received 15 358,466 80,585 Capital repayments from investments in subsidiaries 4,5 821,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 5 563 - Universet received 2,772 11,726 11,726 New loans 6,7 (244,296) (377,830) Repayment loans 6,7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (62,234) (3,292) Contribution shareholders 10.2 (166,345) (621,034)		14	(3,332,971)	5,222,844
Other adjustments (190) (18) Change in other receivables (32) 284 Change in other current liabilities 1,494 4,494 Cash flows from net foreign exchange results (43,244) (14,769) Income taxes paid (122) (56) Net cash used in operating activities (52,609) (16,954) Cash flows from investing activities (52,609) (16,954) Cash flows from investing activities (52,609) (16,954) Cash flows from investing activities (52,609) (16,954) Contribution payments to and acquisition of investments in subsidiaries 4,5 (1,087,567) (4,368,353) Disposal of other investments 5 563	Income tax expense	20	122	166
Change in other receivables(10,705)(6,907)Change in other current liabilities(32)284Change in other current liabilities1,4944,494Cash flows from net foreign exchange results(43,244)(14,769)Income taxes paid(122)(56)Net cash used in operating activities(52,609)(16,954)Cash flows from investing activities15358,46680,585Capital repayments from investments in subsidiaries4,5821,6081,090,817Contribution payments to and acquisition of investments in subsidiaries4,5(1,087,567)(4,368,353)Disposal of other investments5563-Interest received6,7(244,296)(377,830)Repayment loans6,7(244,296)(37,830)Repayment loans6,763,570399,154Acquisition of property, plant and equipment41-Net cash used in investing activities(62,1,034)(3,921)Cash flows from financing activities10.240,00015,000Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)(3,974,500)Net cash used from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Finance income and finance expenses	17		
Change in other receivables(32)284Change in other current liabilities1,4944,494Cash flows from net foreign exchange results(43,244)(14,769)Income taxes paid(122)(56)Net cash used in operating activities(52,609)(16,954)Cash flows from investing activities15358,46680,585Capital repayments from investments in subsidiaries4,5821,6081,090,817Contribution payments to and acquisition of investments in subsidiaries4,5(1,087,567)(4,368,353)Disposal of other investments5563-Interest received2,77211,726New loans6,7(244,296)(377,830)Repayment loans6,763,570399,154Acquisition of property, plant and equipment41-Net cash used in investing activities10.2(166,345)(621,034)Contribution shareholders10.2(166,345)(621,034)Contribution shareholders10.240,00015,000Interest paid (including settlement of derivatives)12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repay	Other adjustments			
Change in other current liabilities1,4944,494Cash flows from net foreign exchange results(43,244)(14,769)Income taxes paid(122)(56)Net cash used in operating activities(52,609)(16,954)Cash flows from investing activities15358,46680,585Capital repayments from investments in subsidiaries4,5821,6081,090,817Contribution payments to and acquisition of investments in subsidiaries4,5(1,087,567)(4,368,353)Disposal of other investments5563Interest received2,77211,726(37,830)399,154Acquisition of property, plant and equipment41Net cash used in investing activities(6,24,034)(3,163,901)(37,830)Cash flows from financing activities10.2(166,345)(621,034)Contribution shareholders10.2(166,345)(621,034)Contribution shareholders10.2(10,000)15,000Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)(3,921)New borrowings12497,2355,628,787Repayment brancing activities222,144930,548Movement in cash and cash equivalents2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916			(10,705)	(6,907)
Cash flows from net foreign exchange results (43,244) (14,769) Income taxes paid (122) (56) Net cash used in operating activities (52,609) (16,954) Cash flows from investing activities (53,58,66) 80,585 Capital repayments from investments in subsidiaries 4,5 821,608 1,090,817 Contribution payments to and acquisition of investments in 4,5 (1,087,567) (4,368,353) Disposal of other investments 5 5663 - Interest received 2,772 11,726 New loans 6,7 (624,296) (377,830) Repayment loans 6,7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (62,1,034) (3,163,901) Cash flows from financing activities (62,23) (3,292) Net cash used in investing activities (6,234) (3,292) Net cash used in investing activities (6,234) (3,921) Cash flows from financing activities (6,234) (3,921)	Change in other receivables		(32)	284
Income taxes paid (122) (56) Net cash used in operating activities (52,609) (16,954) Cash flows from investing activities 15 358,466 80,585 Capital repayments from investments in subsidiaries 4, 5 821,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 4, 5 (1,087,567) (4,368,353) Disposal of other investments 5 563 - Interest received 2,772 11,726 New loans 6, 7 (244,296) (377,830) Repayment loans 6, 7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (142,512) (113,784) Contribution shareholders 10.2 (166,345) (621,034) Contribution shareholders 10.2 (142,512) (113,784) Bank fees (6,234) (3,921) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 (3,974,50	Change in other current liabilities		1,494	4,494
Net cash used in operating activities (52,609) (16,954) Cash flows from investing activities 15 358,466 80,585 Capital repayments from investments in subsidiaries 4,5 821,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 4,5 (1,087,567) (4,368,353) Disposal of other investments 5 563 - Interest received 2,772 11,726 New loans 6,7 (244,296) (377,830) Repayment loans 6,7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (142,512) (113,784) Contribution share holders 10.2 (166,345) (621,034) Contribution shareholders 10.2 (142,512) (113,784) Bank fees (6,234) (3,921) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 (3,974,500) (3,974,500) Net cash from financing activities	Cash flows from net foreign exchange results		(43,244)	(14,769)
Cash flows from investing activities15358,46680,585Dividends received15358,46680,585Capital repayments from investments in subsidiaries4, 5821,6081,090,817Contribution payments to and acquisition of investments in subsidiaries4, 5(1,087,567)(4,368,353)Disposal of other investments5563-Interest received2,77211,726New loans6, 7(244,296)(377,830)Repayment loans6, 763,570399,154Acquisition of property, plant and equipment41-Net cash used in investing activities(84,843)(3,163,901)Cash flows from financing activities(84,843)(3,163,901)Repayment of share premium10.2(166,345)(621,034)Contribution shareholders10.240,00015,000Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)New borrowings12497,2355,628,787Repayment borrowings12(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Income taxes paid		(122)	(56)
Dividends received 15 358,466 80,585 Capital repayments from investments in subsidiaries 4,5 821,608 1,090,817 Contribution payments to and acquisition of investments in subsidiaries 4,5 (1,087,567) (4,368,353) Disposal of other investments 5 563 - Interest received 2,772 11,726 New loans 6,7 (244,296) (377,830) Repayment loans 6,7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (84,843) (3,163,901) Cash flows from financing activities 10.2 (166,345) (621,034) Contribution share premium 10.2 (166,345) (621,034) Contribution shareholders 10.2 (113,784) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 497,235 5,628,787 Repayment borrowings 12 497,235 5,628,787 Repayment borrowings	Net cash used in operating activities		(52,609)	(16,954)
Capital repayments from investments in subsidiaries4, 5821,6081,090,817Contribution payments to and acquisition of investments in subsidiaries4, 5(1,087,567)(4,368,353)Disposal of other investments5563-Interest received2,77211,726New loans6, 7(244,296)(377,830)Repayment loans6, 763,570399,154Acquisition of property, plant and equipment41-Net cash used in investing activities(84,843)(3,163,901)Cash flows from financing activities10.2(166,345)(621,034)Contribution share premium10.2(166,345)(621,034)Contribution share holders10.2(142,512)(113,784)Bank fees(6,234)(3,921)(3,974,500)New borrowings12497,2355,622,787Repayment borrowings12497,2355,622,787Repayment borrowings12(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Cash flows from investing activities			
Contribution payments to and acquisition of investments in subsidiaries4, 5(1,087,567)(4,368,353)Disposal of other investments5563-Interest received2,77211,726New loans6, 7(244,296)(377,830)Repayment loans6, 763,570399,154Acquisition of property, plant and equipment41-Net cash used in investing activities(84,843)(3,163,901)Cash flows from financing activities(84,843)(3,163,901)Cash flows from financing activities(142,512)(1113,784)Bank fees(6,234)(3,921)New borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment in cash and cash equivalents222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Dividends received	15	358,466	80,585
subsidiaries 4, 5 (1,087,567) (4,368,353) Disposal of other investments 5 563 - Interest received 2,772 11,726 New loans 6, 7 (244,296) (377,830) Repayment loans 6, 7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (84,843) (3,163,901) Cash flows from financing activities (84,843) (3,163,901) Cash flows from financing activities (621,034) (621,034) Contribution share premium 10.2 (166,345) (621,034) Contribution shareholders 10.2 40,000 15,000 Interest paid (including settlement of derivatives) (142,512) (113,784) Bank fees (6,234) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 (3,974,500) (3,974,500) Net cash from financing activities 222,144 930,548 Movement in cash and cash equiv	Capital repayments from investments in subsidiaries	4, 5	821,608	1,090,817
Disposal of other investments 5 563 - Interest received 2,772 11,726 New loans 6, 7 (244,296) (377,830) Repayment loans 6, 7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (84,843) (3,163,901) Cash flows from financing activities (84,843) (3,163,901) Repayment of share premium 10.2 (166,345) (621,034) Contribution shareholders 10.2 (166,345) (621,034) Interest paid (including settlement of derivatives) (142,512) (113,784) Bank fees (6,234) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 - (3,974,500) Net cash from financing activities 222,144 930,548 Movement in cash and cash equivalents 2,672,667 2,901,888 Effect of exchange rate changes on cash and cash equivalents 5,715 19,916	Contribution payments to and acquisition of investments in			
Interest received2,77211,726New loans6,7(244,296)(377,830)Repayment loans6,763,570399,154Acquisition of property, plant and equipment41-Net cash used in investing activities(84,843)(3,163,901)Cash flows from financing activities(84,843)(3,163,901)Cash flows from financing activities(621,034)Repayment of share premium10.2(166,345)Contribution shareholders10.2(166,345)Interest paid (including settlement of derivatives)(142,512)Bank fees(6,234)(3,921)New borrowings12497,235Repayment borrowings12(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	subsidiaries	4, 5	(1,087,567)	(4,368,353)
New loans 6, 7 (244,296) (377,830) Repayment loans 6, 7 63,570 399,154 Acquisition of property, plant and equipment 41 - Net cash used in investing activities (84,843) (3,163,901) Cash flows from financing activities (84,843) (621,034) Contribution shareholders 10.2 (166,345) (621,034) Contribution shareholders 10.2 (142,512) (113,784) Bank fees (6,234) (3,921) (3,974,500) New borrowings 12 497,235 5,628,787 Repayment in cash and cash equivalents 222,144 930,548 Movement in cash and cash equivalents 2,672,667 2,901,888 Effect of exchange rate changes on cash and cash equivalents 5,715 19,916	Disposal of other investments	5	563	-
Repayment loans6, 763,570399,154Acquisition of property, plant and equipment41-Net cash used in investing activities(84,843)(3,163,901)Cash flows from financing activities(84,843)(3,163,901)Repayment of share premium10.2(166,345)(621,034)Contribution shareholders10.240,00015,000Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)New borrowings12497,2355,628,787Repayment borrowings12(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Interest received			
Acquisition of property, plant and equipment41Net cash used in investing activities(84,843)(3,163,901)Cash flows from financing activities(84,843)(3,163,901)Repayment of share premium10.2(166,345)(621,034)Contribution shareholders10.2(166,345)(621,034)Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)New borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment borrowings12222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	New loans		(244,296)	(377,830)
Net cash used in investing activities(84,843)(3,163,901)Cash flows from financing activities10.2(166,345)(621,034)Contribution shareholders10.240,00015,000Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)New borrowings12497,2355,628,787Repayment borrowings12-(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916		6, 7		399,154
Cash flows from financing activities10.2(166,345)(621,034)Repayment of share premium10.2(166,345)(621,034)Contribution shareholders10.240,00015,000Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)New borrowings12497,2355,628,787Repayment borrowings12497,2355,628,787Repayment borrowings12(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Acquisition of property, plant and equipment		41	-
Repayment of share premium 10.2 (166,345) (621,034) Contribution shareholders 10.2 40,000 15,000 Interest paid (including settlement of derivatives) (142,512) (113,784) Bank fees (6,234) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 497,235 5,628,787 Net cash from financing activities 222,144 930,548 Movement in cash and cash equivalents 84,692 (2,250,307) Cash and cash equivalents as of 1 January 2,672,667 2,901,888 Effect of exchange rate changes on cash and cash equivalents 5,715 19,916	Net cash used in investing activities		(84,843)	(3,163,901)
Contribution shareholders10.240,00015,000Interest paid (including settlement of derivatives)(142,512)(113,784)Bank fees(6,234)(3,921)New borrowings12497,2355,628,787Repayment borrowings12-(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Cash flows from financing activities			
Interest paid (including settlement of derivatives) (142,512) (113,784) Bank fees (6,234) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 497,235 (3,974,500) Net cash from financing activities 222,144 930,548 Movement in cash and cash equivalents 84,692 (2,250,307) Cash and cash equivalents as of 1 January 2,672,667 2,901,888 Effect of exchange rate changes on cash and cash equivalents 5,715 19,916	Repayment of share premium	10.2	(166,345)	(621,034)
Bank fees (6,234) (3,921) New borrowings 12 497,235 5,628,787 Repayment borrowings 12 497,235 (3,974,500) Net cash from financing activities 222,144 930,548 Movement in cash and cash equivalents 84,692 (2,250,307) Cash and cash equivalents as of 1 January 2,672,667 2,901,888 Effect of exchange rate changes on cash and cash equivalents 5,715 19,916	Contribution shareholders	10.2		
New borrowings 12 497,235 5,628,787 Repayment borrowings 12 - (3,974,500) Net cash from financing activities 222,144 930,548 Movement in cash and cash equivalents 84,692 (2,250,307) Cash and cash equivalents as of 1 January 2,672,667 2,901,888 Effect of exchange rate changes on cash and cash equivalents 5,715 19,916	Interest paid (including settlement of derivatives)		(142,512)	
Repayment borrowings12(3,974,500)Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents1219,916				
Net cash from financing activities222,144930,548Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	-		497,235	
Movement in cash and cash equivalents84,692(2,250,307)Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Repayment borrowings	12	-	(3,974,500)
Cash and cash equivalents as of 1 January2,672,6672,901,888Effect of exchange rate changes on cash and cash equivalents5,71519,916	Net cash from financing activities		222,144	930,548
Effect of exchange rate changes on cash and cash equivalents 5,715 19,916	Movement in cash and cash equivalents		84,692	(2,250,307)
			2,672,667	2,901,888
Cash and cash equivalents as of 30 June 9 2,763,074 671,497	Effect of exchange rate changes on cash and cash equivalents		5,715	19,916
	Cash and cash equivalents as of 30 June	9	2,763,074	671,497

¹⁾ Comparative information has been re-presented due to a change in presentation currency from EUR to US Dollar.

Notes to the Interim Condensed financial statements

1. General information

JAB Holdings B.V. (the "Company") is a company domiciled in the Netherlands and is registered under number 34233247 in the Trade Register. The address of the Company's registered office is Piet Heinkade 55, 1019 GM Amsterdam, the Netherlands. The objectives of the Company are to act as a holding and finance company.

The Company's sole shareholder is JAB Investments S.à r.l. ("JAB Investments"), domiciled in Luxembourg. Ultimate parent is Agnaten SE, Luxembourg.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company's annual financial statements for the year ended 31 December 2020, as they provide an update of previously reported information. They do not include all of the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the last annual financial statements.

Since the end of the last annual reporting period, the impact of Covid-19 on the economic activities have recovered.

JAB Group has a key focus on assessment of the impact of the Covid-19 pandemic on its investments and their performance. It continues to monitor and follow closely the information released from governments, regulatory bodies and health organisations in the countries in which JAB Group and its investments operate.

2. Statement of compliance

The interim condensed financial statements for the six months period ended 30 June 2021 have been prepared applying the same accounting policies as are applied in the Company's annual financial statements, except for the changes described below.

The Company's annual financial statements have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union ("IFRS").

The interim condensed financial statements for the six months period ended 30 June 2021 have been prepared in accordance with IAS 34 – Interim Financial Reporting as adopted by the European Union.

3. Significant accounting policies

The interim condensed financial statements require the management to make judgements, estimates and assumptions that effect the application of policies and reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates, especially in relation to the impact of the Covid-19 pandemic, and the results reported should not be regarded as necessarily indicative of results that may be expected for the entire year.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of revision and future periods if the revision affects both current and future periods. The significant judgements made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the annual financial statements as at and for the year ended 31 December 2020.

In addition, significant judgement was applied in determining the Company's currency and the trigger for a change. The Company's conclusion that the functional currency has changed from Euro to US Dollar was based on an analysis of the underlying economic environment considering the relevant currency's impact on the Company's finance investment and finance activities.

3.1 Changes in accounting policies and disclosures

Except as described below, the accounting policies applied by the Company for the interim condensed financial statements are consistent with those described in the financial statements 2020. In addition, IFRS 2 was applied for the first time in the six months period ended 30 June 2021 with the Company as a service receiving entity in a group share-based payment transaction. Accounting policy is explained under Note 11 Share-based payments.

New standards, amendments, and interpretations

The Company has applied the following standards and amendments for the first time for the annual reporting period commencing 1 January 2021:

- Interest rate benchmark reform amendments to IFRS 9, IAS 39, IFRS 7 and IFRS 16
- Covid 19-related rent concessions amendment to IFRS 16

The amendments listed above did not have any impact on the amounts recognised in current and prior periods and are not expected to significantly affect future periods.

New standards, amendments and interpretations issued, but not effective and adopted yet

Certain new accounting standards have been published that are not mandatory for 30 June 2021 reporting periods and have not been early adopted. The company is still investigating the impact on the Company in the current or future reporting periods and on foreseeable future transactions.

3.2 Change in functional currency and presentation currency

In the previous periods, the primary economic environment in which the Company operates has been changing, with investment and financing activities based on US Dollars (USD) becoming predominant. This change of the Company's primary economic environment from being Euro (EUR) to becoming USD has taken place gradually over time, including gradual move of primary investment currency as well as ongoing developments in the currency profile of the Company's outstanding debt position. As a result of these changes, effective from 1 January 2021, the functional currency of the Company changed prospectively from EUR to USD in compliance with the requirements of IAS 21, *The Effects of Changes in Foreign Exchange Rates*.

The prior year financial statements and interim condensed financial statements were prepared in EUR. In 2021, management decided to change the presentation currency from EUR to USD to align with the functional currency change. The Company has restated prior periods for this presentational change in line with IAS 8, *Accounting Policies, changes in Accounting Estimates and Errors*.

The assets and liabilities and items of equity for periods prior to the change in functional currency were translated into the Company's presentation currency, the USD, using exchange rates prevailing at the end of each reporting period. Income and expenses were translated using the average foreign exchange rate for the reporting period except for dividend income translated at the foreign exchange rate prevailing at the date of the transaction. Exchange differences arising were recognised in other comprehensive income and accumulated in equity. For items included in the statement of cash flows a combination of the period closing rate (for the translation of cash and cash equivalents), the foreign exchange rate prevailing at the date of transaction (for the translation of material cash transactions) and the average rate for the period (for the translations of other transactions) is used.

The exchange rates EUR against the USD used for the change in presentation currency are as follows:

-	31 December 2019	1.1234
-	30 June 2020	1.1198
-	31 December 2020	1.2271
-	Average rate for the six months period ended 30 June 2020	1.1020

4. Investments in subsidiaries

At the end of the period, the Company holds interests in the following investments in subsidiaries:

		Proportion of ownership interest		Fair Value of inter	=
	Principal place	30 June 2021	31 Dec. 2020	30 June 2021	31 Dec. 2020
	of business	%	%	in \$k	in \$k
JAB Forest B.V.	Netherlands	100.0	100.0	18,428,794	17,699,584
JDE Peet's N.V.	Netherlands	-	1.9	0	431,822
Keurig Dr Pepper Inc.	USA	-	0.4	0	173,584
JAB Forest			-	18,428,794	18,304,990
Pret Panera Holdings B.V.	Netherlands	57.4	-	5,015,967	0
Pret Panera I G.P.	USA	-	53.8	0	2,769,459
Pret Panera III G.P.	USA	-	16.3	0	1,359,897
Pret Panera			-	5,015,967	4, 129, 356
JAB Indulgence B.V.	Netherlands	100.0	-	1,030,658	0
KK G.P.	USA	0.0	49.4	1	1,067,980
JAB Indulgence			_	1,030,659	1,067,980
JAB Cosmetics B.V.	Netherlands	100.0	100.0	4,238,905	3,227,471
Petcare G.P.	USA	40.0	38.5	4,803,530	3,273,901
JAB Holding Sao Paulo Ltda.	Brazil	99.9	99.9	374	417
JAB Luxury GmbH	Switzerland	100.00	100.0	250,307	245,956
JAB Ventures B.V.	Netherlands	100.00	0.0	193,164	0
Others				28,778	0
Total			-	33,990,478	30,250,071

The Company controls its investments in KK G.P. and Petcare G.P. by virtue of agreements with its other shareholders. Therefore, the investments are presented as investments in subsidiaries.

JAB Forest B.V.

The Company is invested in Keurig Dr Pepper Group (KDP) and JDE Peet's (JDEP) through JAB Forest B.V. and its intermediate holding company JAB Coffee & Beverages B.V.

In the six months period ended 30 June 2021, the Company acquired further shares in JDE Peet's N.V. (\$37.6m). The Company reorganised its shareholding in KDP and JDEP by transferring either through contribution or sale its directly held shares in JDE Peet's N.V. to JAB Coffee & Beverages B.V. and Keurig Dr Pepper Inc. to JAB Forest B.V. which were subsequently transferred to JAB Coffee & Beverages B.V.

In addition, in the six months period ended 30 June 2021, the Company made a cash contribution of \$499.1m to JAB Forest B.V.

Pret Panera

Pret Panera Holdings B.V. is the direct shareholder of further interim holding companies and their investments in Pret A Manger Group, Panera Brands and Espresso House.

In the six months period ended 30 June 2021, the Company reorganised its shareholding in Pret Panera. The direct investments in Pret Panera I G.P. and Pret Panera III G.P. were contributed to the newly established intermediate holding company Pret Panera Holdings B.V.

JAB Indulgence B.V. / KK G.P.

The Company is invested in Krispy Kreme Group through JAB Indulgence B.V.

In the six months period ended 30 June 2021, the Company reorganised its shareholding in Krispy Kreme. The direct investment in KK G.P. was transferred to the newly established intermediate holding company JAB Indulgence B.V.

In the six months period ended 30 June 2021, the Company made capital contributions to KK G.P. in the amount of \$67.7m. and received share premium repayments of \$158.5m from JAB Indulgence B.V.

JAB Cosmetics B.V.

The Company is invested in Coty Inc. through JAB Cosmetics B.V. and its intermediate holding company Cottage Holdco B.V. As of 30 June 2021, Cottage Holdco B.V. holds 60.6% (463,853,684 shares) in Coty Inc.

Petcare G.P.

The Company is invested in National Veterinary Associates (NVA) through a 40% investment in Petcare G.P. ('Petcare Group').

In the six months period ended 30 June 2021, the Company made additional contributions of \$402.0m to Petcare G.P.

The movements in the investments in subsidiaries can be detailed as follows:

	JAB Forest in \$k	Pret Panera in \$k	JAB Indulgence in \$k	JAB Cosmetics in \$k	Petcare in \$k	JAB Holding Sao Paulo Ltda. in \$k	JAB Luxury GmbH in \$k	JAB Ventures in \$k	Others in \$k	Balance as of 30 June 2021 in \$k
Balance as of										
31 December 2020	18,304,990	4,129,356	1,067,980	3,227,471	3,273,901	417	245,956	-	-	30,250,071
Additions	536,722	-	67,733	-	402,000	-	-	8,000	28,778	1,043,233
Disposals	(392,347)	-	(158,500)	-	-	-	-	-	-	(550,847)
Transfer from other										
investments	-	-	-	-	-	-	-	133,805	-	133,805
Change in fair value	(20,571)	886,611	53,446	1,011,434	1,127,629	(43)	4,351	51,359	-	3,114,216
Balance as of	40,400,704	5 045 067	4 020 050	4 000 005	4 999 599	274	050 007	402.404	00 770	22 000 470
30 June 2021	18,428,794	5,015,967	1,030,659	4,238,905	4,803,530	374	250,307	193,164	28,778	33,990,478

5. Other investments

The following table gives an overview of other investments:

	30 June	30 June 2021		er 2020
	Short-term in \$k	Long-term in \$k	Short-term in \$k	Long-term in \$k
Corporate debt securities Panera Brands, Inc.	<u>.</u>	213,803		
Derivatives	-	213,003	-	-
Other derivatives	-	-	447	-
Others	-	50,094	-	131,713
	-	263,897	447	131,713

Corporate debt securities

On 25 January 2021, the Company acquired 270.7 thousand preference shares together with 1.6 million warrants in Panera Brands, Inc., at an amount of \$270.7m for the combined instrument. The preference shares were issued with a nominal value of \$0.01 and a 7% coupon dividend and the warrants have an exercise price of \$0.01, with 0.5 million warrants being subject to a 3-year prorata vesting condition. Both, the preferred shares and the warrants, are measured at FVTPL.

On 7 May 2021, the preference shares were redeemed by the issuer at 102% of the nominal value. The total redeemed value was \$281.5m, including \$5.3m of coupon dividends.

The fair value of the vested warrants as of 30 June 2021 was determined using the fair value of the Panera Brands, Inc. ordinary share price, for the warrants that are exercisable at the reporting date. Unvested warrants were valued at zero as of 30 June 2021.

The movements in the other investments can be detailed as follows:

	Corporate debt securities in \$k	Derivatives in \$k	Others in \$k	Total in \$k
Balance as of 31 December 2020	-	447	131,713	132,160
Additions Disposal Transfer to investments in subsidiaries	270,681 (276,169) -	- (563) -	52,838 - (133,805)	323,519 (276,732) (133,805)
Change in fair value	219,291	116	(652)	218,755
Balance as of 30 June 2021	213,803	0	50,094	263,897

6. Loans to investments

The movements in the loans can be detailed as follows:

	Pret Panera
	in \$k
Balance as of 31 December 2020	117,089
Additions	225,771
Repayments	(63,570)
Conversion to debt instruments in the other	
investments	(270,681)
Translation differences	475
Balance as of 30 June 2021	9,084
Thereof non-current	-
Thereof current	9,084

7. Other loans

	30 June 2021 in \$k	31 December 2020 in \$k
JAB Management	26,099	46,854
JAB Holding Company LLC	4,535	4,013
	30,634	50,867
Thereof non-current	-	-
Thereof current	30,634	50,867

8. Other assets

	30 June 2021 in \$k	31 December 2020 in \$k
Property, plant and equipment	1,381	2,647
Prepayments	6,224	7,135
Other receivables	2,046	6,110
	9,651	15,892

9. Cash and cash equivalents

Cash and cash equivalents as of 30 June 2021 include bank deposits and liquidity funds available on demand in the amount of \$2,112.7m (31 December 2020: \$795.9m) and deposits with maturity in July 2021 in the amount of \$650.3m (31 December 2020: \$390.1m with maturity in January 2021; \$300.0m in February 2021 and \$1,186.6 in March 2021).

10. Shareholder's equity

10.1 Share capital

The authorised share capital amounts to \$ 116,451 (€90,000; 1,800 shares), of which 363 shares of \$59 (€50) each (total \$23,484, €18,150; 31 December 2020: 363 shares, €18,150, \$23,484) have been issued and fully paid.

As of 30 June 2021 and 31 December 2020, no shares in the entity are held by the Company or by its subsidiaries or associates.

10.2 Share premium

In the six months period ended 30 June 2021, the Company received cash contributions to the share premium in the amount of \$40.0m (six months ended 30 June 2020: \$15.0m).

In the reporting period, the Company partly returned the share premium in cash in the amount of \$141.6m (six months ended 30 June 2020: \$621.0m).

For changes in the share premium relating to share-based payments, please refer to note 11.

10.3 Legal reserve

As of 30 June 2021, pursuant to Dutch law (Book 2 Title 9 of the Netherlands Civil Code art. 390), certain limitations exist relating to the distribution of shareholders' equity. The limitations for the company relate to the revaluations of assets without a frequent market listing in the amount of \$15,551.8m (31 December 2020: \$11,877.9m).

10.4 Retained earnings

In the six months period ended 30 June 2021, no dividend was paid to the parent company JAB Investments S.à r.l. out of retained earnings (six months ended 30 June 2020: \$0.0m).

11. Share-based payments

The Company's indirect shareholder JAB Holding Company S.à r.l. operates share grant agreements and share option schemes with the members of the management team and executives and senior managers of JAB Holding Company S.à r.l. and its affiliates. All share-based payment agreements are based on shares in JAB Holding Company S.à r.l.

As of 2021, members of the Company's management team are party to such share-based payment agreements with the Company as service-receiving entity from such agreements. The Company classifies those agreements as equity-settled share-based payment transactions and accounts them in line with IFRS 2, *Share-based payment*. The share-based payment transactions include share grant agreements (special awards to purchase shares under service conditions, limited recourse loans to purchase shares) and share option schemes.

Share-based payment transactions are recognised over the period in which the performance and/or service conditions are fulfilled. Equity-settled transactions are recognised in share premium in equity. The cumulative expense recognised for share-based payment transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of instruments that will ultimately vest. Equity-settled transactions are measured at the grant date fair value of the equity instruments granted, i.e. shares in JAB Holding Company S.à r.l.

Share grant agreements

The special awards to purchase shares have graded vesting conditions and they vest over a vesting period of 5 years. The expense is based on the grant date fair value of the shares purchased from the award. The impact of service conditions is not included in the fair value measurement of the grant. It is expected that all service conditions are fully met. The expense for loan funded share purchases with limited recourse which are accounted for as an option-plan under IFRS 2 is measured using option pricing models (Black-Scholes).

The expense recognised arising from share grant agreements during the period was \$3.7m.

The share grant agreements contain in economic substance a recharge from JAB Holding Company S.à r.l. to the Company. The recharge is recognised directly in equity as a return of the capital contribution recorded as the credit to equity required by IFRS 2 up to the amount of that contribution (\$3.7m) and as a distribution from the subsidiary to its parent, if the recharge exceeds the capital contribution (\$66.3m).

Share option schemes

The share options have cliff vesting features and they vest over a service period of 5 years. Options may be exercised at any time from the vesting date to the date of their expiry (10 years from the grant date). All options related to share-based compensation plans were granted with an exercise price (in USD) being an approximate to the underlying shares in JAB Holding Company S.à r.l. at the grant date.

The fair value of each option granted is estimated using the Black-Scholes option-pricing model. The expense recognised arising from share option schemes with JAB Holding Company S.à r.l. during the period was \$4.2m. The share options schemes do not provide for a recharge from JAB Holding Company S.à r.l. to the Company.

12. Borrowings

The movements in borrowings can be detailed as follows:

	Long-term notes	Bank loan	Total
	in \$k	in \$k	in \$k
Balance as of 31 December 2020	10,028,892	245,420	10,274,312
Additions / Repayments	491,967	-	491,967
Amortisation disagio and fees	5,535	-	5,535
Translation differences	(303,093)	(7,741)	(310,835)
Balance as of 30 June 2021	10,223,301	237,679	10,460,980
Thereof non-current	9,658,266	-	9,658,266
Thereof current	565,035	237,679	802,714

Overview of borrowings issued in the six months period ended 30 June 2021

Note	Original Principal	Remaining Principal	Issued	Due	Carrying value 30 June 2021 in \$k
Senior Note 2051	\$500,000	\$500,000	May 2021	May 2051	492,179

Note Additional issuances

Senior Note 2051 In May 2021, the Company issued long-term notes in the aggregate principal amount of \$500.0m at an interest rate of 3.75% p.a. The notes represent a private placement in the US market.

As of 30 June 2021, the Company has no outstanding payables under its credit facilities (31 December 2020: \$0.0m).

13. Other liabilities

	30 June 2021	31 December 2020
	in \$k	in \$k_
Accrued interest and other bank fees	50,400	87,601
Lease liability	1,463	1,584
Derivatives	0	1,827
Other liabilities	11,580	6,471
	63,443	97,483
thereof current	62,127	96,048
thereof non-current	1,316	1,435

14. Net gain / (loss) on investments in subsidiaries and other investments

	For the six months ended 30 June 2021	For the six months ended 30 June 2020
-	in \$k	in \$k
Net gain / (loss) on investments in subsidiaries at FV	TPI	
JAB Forest B.V.	231	(921,051)
Acorn Holdings B.V.	67,523	(149,003)
Keurig Dr Pepper Inc.	(6,075)	(2,717)
JDE Peet's N.V.	(82,250)	48,068
JAB Forest	(20,571)	(1,024,703)
Pret Panera	886,611	-
Pret Panera I G.P.	-	(583,308)
Pret Panera III G.P.	-	(286,424)
Pret Panera	886,611	(869,732)
JAB Indulgence B.V.	53,446	-
KK G.P.	-	(28,489)
JAB Indulgence	53,446	(28,489)
JAB Cosmetics B.V.	1,011,434	(3,127,526)
JAB Holding Company Ltda.	(43)	(1,875)
Petcare G.P.	1,127,629	(51,478)
JAB Luxury GmbH	4,351	(216,671)
JAB Ventures B.V.	51,359	-
_	3,114,216	(5,320,474)
Net gain on other investments at FVTPL		
Others	(536)	87,117
Corporate debt securities	219,291	10,513
•	218,755	97,630
	3,332,971	(5,222,844)

15. Dividend income

In the six months period ended 30 June 2021, the Company recognised dividend income from the following investments measured at FVTPL:

	For the six months ended	For the six months ended
	30 June 2021	30 June 2020
	in \$k	in \$k
JAB Indulgence B.V.	227,500	-
JAB Forest B.V.	124,886	70,376
Panera Brands, Inc.	5,267	-
Keurig Dr Pepper Inc.	813	1,110
Acorn Holdings B.V. preferred dividend	-	9,099
	358,466	80,585

16. Net income from investments at FVTPL

Financial assets measured at FVTPL	For the six months ended 30 June 2021 in \$k	For the six months ended 30 June 2020 in \$k
Investments in subsidiaries Other investments	3,467,415 224,022	(5,248,988) 106,729
	3,691,437	(5,142,259)

Net income from investments at FVTPL comprises net gain/(loss) on investments in subsidiaries and other investments and dividend income from investments at FVTPL.

17. Finance income and finance expenses

Finance income can be detailed as follows:

	For the six months ended 30 June 2021 in \$k	For the six months ended 30 June 2020 in \$k
Interest income on bank deposits	704	4,162
Interest income on loans and receivables	1,202	4,085
Net foreign exchange gain	277,253	32,665
Other	-	587
	279,159	41,499

In the six months period ended 30 June 2021, foreign exchange gains mainly result from the translation of borrowings denominated in EUR to USD.

Finance expenses can be detailed as follows:

	For the six months ended 30 June 2021 in \$k	For the six months ended 30 June 2020 in \$k
Interest expense on financial liabilities	(105,598)	(99,252)
Bank fees	(7,145)	(4,738)
Valuation of interest rate contracts	-	14,537
	(112,743)	(89,453)

18. General and administrative expenses

General and administrative expenses can be detailed as follows:

	For the six months ended 30 June 2021 in \$k	For the six months ended 30 June 2020 in \$k
Legal, tax, audit and consultancy fees	(4,379)	(907)
Service fees to related parties	(2,916)	(1,778)
Salary and personnel related expenses	(2,869)	(4,014)
Others	(567)	(384)
	(10,731)	(7,083)

19. Other expenses

In the six months period ended 30 June 2021, other expenses in the amount of \$7.9m relate to share-based payments (six months ended 30 June 2020: zero).

20. Taxes on income

The taxable amount for the six months period ended 30 June 2021 amounts to zero (six months ended 30 June 2020: zero) and therefore no corporate income tax expense was recognised.

	For the six months ended 30 June 2021 in \$k	For the six months ended 30 June 2020 in \$k
Withholding tax on investments in subsidiaries	(122)	(166)
	(122)	(166)

Income from investments can be subject to withholding taxes. Withholding taxes have been recognised as part of income tax expense, with the income recognised on a gross basis.

21. Related parties and transactions with related parties

The related parties are disclosed in the Company's annual financial statements for the year ended 31 December 2020. Related party transactions which have taken place in the period and have materially affected the interim condensed financial statements are disclosed in the notes to the interim condensed financial statements.

22. Financial instruments – Fair Value and Risk Management

The Company classifies its financial instruments by category as set out below:

	30 June 2021		31	December 20)20	
	Amortised cost	FVTPL	Total	Amortised cost	FVTPL	Total
	in \$k	in \$k	in \$k	in \$k	in \$k	in \$k
Assets as per statement of financial position						
Investments in subsidiaries	-	33,990,478	33,990,478	-	30,250,071	30,250,071
Other investments	-	263,897	263,897	-	132,160	132,160
Loans to investments	9,084	-	9,084	117,089	-	117,089
Other loans	30,634	-	30,634	50,867	-	50,867
Other assets Cash and cash	9,651	-	9,651	13,244	-	13,244
equivalents	2,763,074	-	2,763,074	2,672,667	-	2,672,667
Total _	2,812,443	34,254,375	37,066,818	2,853,867	30,382,231	33,236,098

	30	30 June 2021			31 December 2020		
	Amortised cost	FVTPL	Total	Amortised cost	FVTPL	Total	
	in \$k	in \$k	in \$k	in \$k	in \$k	in \$k	
Liabilities as per statement of financial posit	ion						
Borrowings	10,460,980	-	10,460,980	10,274,312	-	10,274,312	
Other liabilities	63,443	-	63,443	95,656	1,827	97,483	
Total	10,524,423	-	10,524,423	10,369,968	1,827	10,371,795	

Cash and cash equivalents, as well as other loans and other assets, are subject to the impairment requirements of IFRS 9. As of 30 June 2021 and 31 December 2020, cash and cash equivalents were placed with quality financial institutions and could be withdrawn on short notice. Therefore the expected credit loss on cash and cash equivalents and other loans and other assets, as well as the identified impairment loss for the other loans subject to the expected credit loss model, were immaterial. The following table shows financial instruments carried at fair value by their valuation technique. It does not include fair value information of financial assets and financial liabilities not measured at fair value. The issued long-term notes have a carrying amount of \$10,223.5m (31 December 2020: \$10,028.9m), the fair value is \$10,969.4m (31 December 2020: \$10,948.6m) based on dealer-quotes (Level 2). For all other financial assets and liabilities, the carrying amounts are a reasonable approximate of fair values.

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Financial instruments in Level 1

The fair value of financial instruments traded in active markets is based on quoted market prices at the reporting date. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

As of 30 June 2021, financial instruments included in Level 1 comprise other investments (31 December 2020: Keurig Dr Pepper Inc., JDE Peet's N.V. and other derivatives).

Financial instruments in Level 2

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity-specific estimates. If all significant inputs required to determine fair value an instrument are observable, the instrument is included in Level 2.

Financial instruments included in Level 2 comprise shares in JAB Cosmetics B.V. (31 December 2020: JAB Cosmetics B.V., foreign exchange contracts). Specific valuation techniques used to value these financial instruments include

- JAB Cosmetics B.V. holds 100% of Cottage Holdco B.V. which is direct shareholder in Coty Inc. Coty Inc. is a listed company (New York Stock Exchange). JAB Cosmetics B.V.'s fair value was determined on the basis of its indirect investment in Coty Inc.
- Quoted market prices or dealer quotes for outstanding long-term notes and similar instruments;
- The fair value of forward exchange contracts is determined using forward exchange rates at the reporting date.

Financial instruments in Level 3

If one or more of the significant inputs is not based on observable market data, the instrument is included in Level 3. Financial instruments included in Level 3 comprise shares in JAB Forest B.V., Pret Panera Holdings B.V., JAB Indulgence B.V., JAB Holding Company Ltda., Petcare G.P., JAB Luxury GmbH, corporate debt securities and other investments (31 December 2020: JAB Forest B.V., Pret Panera I G.P., Pret Panera III G.P., KK G.P., JAB Holding Company Ltda., Petcare G.P., JAB Forest B.V., JAB Luxury GmbH and other investments).

	30 June 2021			
	Level 1	Level 2	Level 3	Total
	in \$k	in \$k	in \$k	in \$k
Financial assets at FVTPL Investments in subsidiaries and other investments		4 000 005	00 754 570	00 000 170
Unlisted equity investments	-	4,238,905	29,751,573	33,990,478
Other investments	46,700	-	217,197	263,897
Total assets	46,700	4,238,905	29,968,770	34,254,375

	31 December 2020				
	Level 1 in \$k	Level 2 in \$k	Level 3 in \$k	Total in \$k	
Financial assets at FVTPL Investments in subsidiaries					
Listed equity investments	605,406	-	-	605,406	
Unlisted equity investments	-	3,227,471	26,417,194	29,644,665	
Other investments	447	-	131,713	132,160	
Total assets	605,853	3,227,471	26,548,907	30,382,231	
Financial liabilities at FVTPL					
Other liabilities	-	1,827	-	1,827	
Total liabilities	-	1,827	-	1,827	

In the six months period ended 30 June 2020, FVTPL equity instruments with a carrying amount of \$2,336.0m were transferred from Level 3 to Level 2 as all of the significant inputs required to determine fair value are observable following the omission of significant inputs not observable. To determine the fair value of the equity instruments, management used a valuation technique in which significant inputs were based on observable and unobservable data.

In the six months period ended 30 June 2021, there were no transfers between the levels. There were no transfers from Level 2 or 3 to Level 1 during the six months period ended 30 June 2020.

Transfers between the levels of the fair value hierarchy are deemed to have occurred at the date of the event that caused the transfer.

The following tables show a reconciliation of all movements in the fair value of financial instruments categorised within Level 3 between the beginning and the end of the reporting period.

	Investments in subsidiaries	Other investments	Other investments
	Unlisted equity investments	Unlisted equity investments	Corporate debt securities
	in \$k	in \$k	in \$k
Balance as of 1 January 2021	26,417,194	131,713	-
Additions	1,043,233	5,486	270,681
Disposals	(550,847)	-	(276,169)
Transfer	739,211	(133,805)	-
Change in fair value	2,102,782	-	219,291
Balance as of 30 June 2021	29,751,573	3,394	213,803

Level 3 valuation techniques of equity investments are appropriate in the circumstance and reflect recent transactions and market multiples.

Investments in subsidiaries and other investments categorised in Level 3

The fair value of financial assets in this category is based on different unobservable inputs and observable inputs. The Company's investments include significant direct equity participations or debt securities in JAB Forest B.V., Pret Panera Holdings B.V., JAB Indulgence B.V., Petcare G.P. and JAB Luxury GmbH (31 December 2020: JAB Forest B.V., Pret Panera I G.P., Pret Panera III G.P., KK G.P., Petcare G.P. and JAB Luxury GmbH), none of which are directly quoted in an active market. Unobservable inputs include LTM/NTM results, peer multiples and transaction prices.

Valuation process

The Company uses market-based valuation techniques for its level 3 fair value investments. The market-based valuations are prepared by the Company. The Company receives support in this valuation process from an external service provider. The Company holds directly or through its investment platforms stakes in private and public companies (together referred to as 'underlying investments' or individually 'underlying investment'). The valuations of the underlying investments are reviewed by the valuation committees, which comprise of independent and executive board members of those underlying investments. Once the valuation committee has unanimously approved the valuations, the Company aggregates the valuations of the underlying investments in line with the investment platforms structures. Other portfolio company assets and liabilities are considered in the valuation, together with the aggregated underlying investments against their respective ownership stake. The platform valuations are subsequently approved by the Directors of the platform investments.

Valuation method – public companies

For underlying investments that are publicly traded (KDP, Coty, JDE Peet's and Krispy Kreme), fair value is determined by reference to the quoted market price on the balance sheet closing date. As Krispy Kreme went public on 1 July 2021, the valuation is based on the volume weighted average share price of the first two trading days (\$19.13).

Valuation method – private companies: price of a recent transaction

Underlying investments of private companies that were acquired recently, generally within the last year, or for which a recent market transaction is available, are measured at the transaction price, except where the underlying company's economic performance (e.g. operations, financial position and liquidity) has significantly changed. As part of the analysis, the Company calibrates the price of a recent transaction by using a market approach on a case by case basis.

Valuation method – private companies: market approach using comparable multiples

This valuation method is applied for underlying investments which are not quoted in an active market. In using the market approach to determine the fair value of an underlying investment, a market multiple is established based on a selected group of comparable publicly traded peer group companies that is considered representative of the underlying investment. The determination of the peer group companies is generally based on the risk profile, growth prospect, strength of the brand or brand portfolio, leverage and certain other financial characteristics (e.g. market capitalization, EBITDA margin levels, etc).

The selected multiples are the median of the comparable publicly listed companies and are applied to the figures of the underlying investments as of June 2021 and December 2020. In addition, adjustments between the enterprise value and the equity value are made for financial debt, and, where relevant, for non-controlling interest and financial assets.

The main elements and related sensitivities in the valuations of the privately held underlying investments are:

- The formula of weighted average multiples which include the selected ratios for: price earnings ("P/E"), EV/EBITDA and EV/Sales;
- The multiples of comparable public companies in the peer group based on industry, size, leverage and strategy;
- The selection of forward looking (NTM) or historical market multiples (LTM) for selected peers; and
- The financial inputs from the portfolio companies.

Other considerations

The valuation methods have been applied consistently over time, for which by exception amendments were made due to triggering events (e.g. COVID-19). In the event of the occurrence of a triggering event, such event has been disclosed.

The following table summarises key unobservable inputs for the underlying investments used within the Level 3 fair value measurement of investments in subsidiaries:

Fair value				Range		
			Valuation			
	30 June 2021	31 December 2020	technique	Input	30 June 2021	31 December 2020
Investments in			Publicly listed	Quoted share price		
subsidiaries	29,751.6	26,417.2			N/A	N/A
			Transaction price	Price of a recent		
				transaction	N/A	N/A
			Market approach -	EBITDA multiples		
			Comparable	(LTM)		
			companies		N/A	20.9 - 22.4
				EBITDA multiples		
				(NTM)	12.7 - 19.7	10.0- 19.6
			Market approach -	Sales multiples		
			Comparable	(LTM)		
			companies		N/A	4.6
				Sales multiples		
				(NTM)	1.5 - 4.8	1.2 - 5.0
			Market approach -	P/E multiples		
			Comparable	(LTM)		
			companies		N/A	30.1 - 36.4
				P/E multiples		
				(NTM)	17.0 - 32.3	17.0 - 29.9

Underlying investments valued based on a market approach using comparable companies multiples technique are valued using NTM multiples (Pret Panera Holdings B.V. and JAB Luxury GmbH; 31 December 2020: LTM multiples - KK G.P., Petcare G.P.; NTM multiples – Pret Panera I G.P., Pret Panera III G.P., JAB Luxury GmbH).

As of 30 June 2021, JAB Indulgence is direct shareholder in Krispy Kreme Inc. JAB Indulgence's fair value was determined on the basis of its investment in Krispy Kreme Inc. As Krispy Kreme Inc. went public on 1 July 2021, the valuation is based on the weighted average share price of the first two trading days (\$19.13).

As of 30 June 2021, Petcare G.P.'s fair value was determined based on the transaction price of a recent market transaction.

A weighting is applied to the multiples used to determine the fair value of the investment. The weighting applied depends on various circumstances include the stage at which the company is, resulting in the following weighting:

	30 June 2021		31 December 2020			
	EV/EBITDA	P/E	EV/Sales	EV/EBITDA	P/E	EV/Sales
Pret Panera	40%	40%	20%	40%	40%	20%
JAB Luxury	20%	20%	60%	10%	10%	80%
Petcare	N/A	N/A	N/A	50%	50%	-
KK	N/A	N/A	N/A	40%	40%	20%

As of 30 June 2021, a weighting of 50% EV/EBITDA and 50% P/E was applied for Petcare to calibrate the transaction price of recent transaction by using a market approach.

Sensitivity analysis to unobservable inputs

Changes in the valuation methodologies or assumptions could lead to different measurements of fair value. The most significant unobservable inputs are the applied multiples and transaction prices. The estimated fair value would increase (decrease) if the adjusted market multiples or transaction prices were higher (lower). A change of the applied multiples and transaction prices by 10% would change the fair value estimate as follows:

	30 June	30 June 2021		er 2020
	increase in \$m	decrease in \$m	increase in \$m	decrease in \$m
Pret Panera	630.0	(630.0)	547.6	(547.6)
Petcare	480.4	(480.4)	392.6	(392.6)
KK	141.7	(141.7)	132.9	(132.9)
JAB Luxury	35.9	(35.9)	34.1	(34.1)
	1,288.0	(1,288.0)	1,107.2	(1,107.2)

For the exposure to other price risk from indirect investments in publicly traded companies, please refer sensitivity analysis – equity price risk.

Other financial instruments

Overview financial risk factors

The Company has exposure to the following risks from its use of financial instruments:

- credit risk;
- liquidity risk;
- market risk.

The interim condensed financial statements do not include all financial risk management information and disclosure required in annual financial statements, and should be read in conjunction with the Company's 31 December 2020 financial statements. There have been no changes in risk management policies and procedures since year-end.

Sensitivity analysis – equity price risk

The sensitivity analyses below have been determined on the exposure to equity price risks for direct investments at the end of the reporting period. If share prices had been 5% higher/lower, the result for the six months period ended 30 June 2021 would have increased/decreased by \$2.3m as a result of changes in the fair value of the equity investments classified as at FVTPL (six months period ended 30 June 2020: \$30.3m). Other comprehensive income for six months period ended 30 June 2021 would have been unaffected (six months period ended 30 June 2020: \$0.0m).

Further, the Company has indirect exposure to equity price risks from indirect investments at the end of the reporting period. If share prices had been 5% higher/lower, the result for the period ended 30 June 2021 would have increased/decreased by \$1,248.4m as a result of changes in the fair value of the equity investments classified as at FVTPL (31 December 2020: \$1,207.4m). Other comprehensive income for the six months period ended 30 June 2021 would have been unaffected (six months period ended 30 June 2020: \$0.0m).

There are no further significant assets or liabilities that could be exposed to material direct market risks.

23. Contingent liabilities

The Company along with JAB Cosmetics B.V. and Cottage Holdco B.V. (the "Group Companies") are named as defendant in a stockholder class action and derivative lawsuit pending in the Delaware Court of Chancery under the caption *In re Coty Inc. Stockholders Litigation, Cons. C.A. No. 2019-0336-AGB*. The complaint relates to Cottage Holdco B.V.'s partial tender offer to purchase the stock of Coty, Inc. (the "Tender Offer"). The complaint alleges that the Group Companies acted in concert to control Coty, that the JAB directors of Coty breached their fiduciary duties by approving the Tender Offer, and that the Group Companies breached their fiduciary duties as Coty's controlling stockholder. Plaintiffs contend that the Tender Offer injured the tendering stockholders because it was purportedly unfairly priced, and that the non-tendering stockholders were injured because the Group Companies gained mathematical control of Coty, thereby depriving the non-controlling stockholders of a control premium. The case is currently in the middle of fact discovery. A trial date has not yet been set.

24. Subsequent events

The Company's management has evaluated subsequent events through the date of issuance of the interim condensed financial statements.

In July 2021,

- the Company successfully issued a Eurobond of €500m;
- the Krispy Kreme IPO was completed successfully; between the date of IPO and date of issuance of the interim condensed financial statements, the share price traded between \$12.82 and \$21.69;
- the indirectly held investment in Cottage Holdco B.V. was transferred to the Company's indirect shareholder, JAB Holding Company S.à r.l.

Amsterdam, 31 August 2021

The Board of Directors:

J. Creus

F. Engelen

The Supervisory Board:

P. Harf

O. Goudet



Independent auditor's review report

To: the Board of Directors of JAB Holdings B.V.

Our conclusion

We have reviewed the accompanying Interim Condensed Financial Statements of JAB Holdings B.V.(or hereafter: the "Company") based in Amsterdam. Based on our review, nothing has come to our attention that causes us to believe that Interim Condensed Financial Statements are not prepared, in all material respects, in accordance with IAS 34 'Interim Financial Reporting' as adopted by the European Union.

Interim Condensed Financial Statements comprise:

- 1 the Interim Condensed Statement of Financial Position as of 30 June 2021;
- 2 the following statements for the six months period ended 30 June 2021: the Interim Condensed Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flow Statement; and
- 3 the notes comprising of a summary of the accounting policies and other explanatory information.

Basis for our conclusion

We conducted our review in accordance with Dutch law, including the Dutch Standard 2410, 'Het beoordelen van tussentijdse financiële informatie door de accountant van de entiteit' (Review of interim financial information performed by the independent auditor of the entity). A review of interim financial information in accordance with the Dutch Standard 2410 is a limited assurance engagement. Our responsibilities under this standard are further described in the 'Our responsibilities for the review of the interim financial information of the interim financial information.

We are independent of JAB Holdings B.V. in accordance with the Verordening inzake de onafhankelijkheid van accountants bij assurance-opdrachten (ViO, Code of Ethics for Professional Accountants, a regulation with respect to independence) and other relevant independence regulations in the Netherlands. Furthermore, we have complied with the Verordening gedrags- en beroepsregels accountants (VGBA, Dutch Code of Ethics).

We believe the assurance evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

Responsibilities of the Board of Directors and the Supervisory Board for the Interim Condensed Financial Statements

The Board of Directors is responsible for the preparation and presentation of Interim Condensed Financial Statements in accordance with IAS 34 'Interim Financial Reporting' as adopted by the European Union. Furthermore, management is responsible for such internal control as it determines is necessary to enable the preparation of Interim Condensed Financial Statements that are free from material misstatement, whether due to fraud or error.

The Supervisory Board is responsible for overseeing the Company's financial reporting process.



Our responsibilities for the review of the Interim Condensed Financial Statements

Our responsibility is to plan and perform the review in a manner that allows us to obtain sufficient and appropriate assurance evidence for our conclusion.

The level of assurance obtained in a limited assurance engagement is substantially less than the level of assurance obtained in an audit conducted in accordance with the Dutch Standards on Auditing. Accordingly, we do not express an audit opinion.

We have exercised professional judgement and have maintained professional scepticism throughout the review, in accordance with Dutch Standard 2410.

Our review included among others:

- Updating our understanding of the entity and its environment, including its internal control, and the applicable financial reporting framework, in order to identify areas in the Interim Condensed Financial Statements where material misstatements are likely to arise due to fraud or error, designing and performing procedures to address those areas, and obtaining assurance evidence that is sufficient and appropriate to provide a basis for our conclusion;
- Obtaining an understanding of internal control, as it relates to the preparation of the Interim Condensed Financial Statements;
- Making inquiries of management and others within the entity;
- Applying analytical procedures with respect to information included in the Interim Condensed Financial Statements;
- Obtaining assurance evidence that the Interim Condensed Financial Statements agree with, or reconcile to the entity's underlying accounting records;
- Evaluating the assurance evidence obtained;
- Considering whether there have been any changes in accounting principles or in the methods of applying them and whether any new transactions have necessitated the application of a new accounting principle;
- Considering whether management has identified all events that may require adjustment to or disclosure in the Interim Condensed Financial Statements; and
- Considering whether Interim Condensed Financial Statements has been prepared in accordance with the applicable financial reporting framework and represents the underlying transactions free from material misstatement.

Amstelveen, 31 August 2021

KPMG Accountants N.V.

N.J. Hoes RA